Yahoo
NYSE - Delayed Quote USD

Medtronic plc (MDT)

94.17 +1.07 (+1.15%)
At close: September 4 at 4:00:02 PM EDT
92.74 -1.43 (-1.52%)
After hours: 8:00:00 PM EDT
Trade MDT on Coinbase
Dividend
MDT announced a cash dividend of $0.72 with an ex-date of Sep. 25, 2026
Chart Range Bar
Loading chart for MDT

What's happening with MDT?

37m ago
Powered by Yahoo Scout

Medtronic is showcasing strong fiscal Q1 results with a 13.7% revenue growthand raised guidance for fiscal 2027, signaling a recovery path. Upcoming investor events feature key executives discussing the company's strategy and growth potential.

Powered by Yahoo Scout
  • Previous Close 93.10
  • Open 92.76
  • Bid 94.33 x 70000
  • Ask 94.75 x 40000
  • Day's Range 92.31 - 94.74
  • 52 Week Range 73.31 - 106.33
  • Volume 8,627,339
  • Avg. Volume 8,201,687
  • Market Cap (intraday) 120.456B
  • Beta (5Y Monthly) 0.57
  • PE Ratio (TTM) 23.19
  • EPS (TTM) 4.06
  • Earnings Date (est.) Nov 17, 2026
  • Forward Dividend & Yield 2.88 (3.09%)
  • Ex-Dividend Date Sep 25, 2026
  • 1y Target Est 104.76

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.

www.medtronic.com

95,000

Full Time Employees

April 24

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

MDT
0.28%
S&P 500 (^GSPC)
12.75%

1-Year Return

MDT
4.72%
S&P 500 (^GSPC)
18.71%

3-Year Return

MDT
26.54%
S&P 500 (^GSPC)
70.93%

5-Year Return

MDT
18.19%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY26
Revenue 9.81B
Earnings 1.24B
Profit Margin 12.68%

Q1

FY26

Q2

FY26

Q3

FY26

Q4

FY26

0
2B
4B
6B
8B
13.0%
14.0%
15.0%

Analyst Insights

View More

Analyst Price Targets

85.00 Low
104.76 Average
94.17 Current
121.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/3/2026
Analyst UBS
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 100 -> 110

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.93%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    37.54B

  • Net Income Avi to Common (ttm)

    5.23B

  • Diluted EPS (ttm)

    4.06

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    9.22B

  • Total Debt/Equity (mrq)

    58.21%

  • Levered Free Cash Flow (ttm)

    --

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: